BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30092672)

  • 21. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
    Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
    Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?
    Litzow MR
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):345-350. PubMed ID: 27890258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Huang A; Huang C; Tang G; Cheng H; Liu M; Ding J; Gong S; Chen Q; Zhang W; Yang J; Wang J; Hu X
    Leuk Lymphoma; 2018 May; 59(5):1073-1083. PubMed ID: 28857648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Seol CA; Cho YU; Jang S; Park CJ; Lee JH; Lee JH; Lee KH; Seo EJ
    Cancer Genet; 2017 Oct; 216-217():29-36. PubMed ID: 29025593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.
    Herold T; Gökbuget N
    Curr Oncol Rep; 2017 May; 19(5):31. PubMed ID: 28361222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
    Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
    Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
    Radich JP
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):91-103. PubMed ID: 11987918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How has the management of Ph
    Chiaretti S; Foà R
    Rinsho Ketsueki; 2016; 57(10):2038-2048. PubMed ID: 27795512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
    Zhang W; Jang E
    PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
    Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
    Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
    Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Mercadal S; González-Campos J; Moreno MJ; Barba P; Cervera M; Barrios M; Novo A; Bernal T; Hernández-Rivas JM; Abella E; Amigo ML; Tormo M; Martino R; Lavilla E; Bergua J; Serrano A; García-Belmonte D; Guàrdia R; Grau J; Feliu E;
    Leuk Lymphoma; 2018 Jan; 59(1):146-154. PubMed ID: 28554259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
    Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
    Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
    Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
    Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Potter M; Poiré X; Sengeloev H; Socié G; Huynh A; Afanasyev BV; Schanz U; Ringden O; Kalhs P; Beelen DW; Campos AM; Masszi T; Canaani J; Mohty M; Nagler A
    Eur J Cancer; 2018 Jun; 96():73-81. PubMed ID: 29679774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.